- Clinical Expertise
- Hematology
- Leukemia & Myeloma
- Board Certifications
- Internal Medicine
- Hematology
- Oncology
- Appointments
- Assistant Professor of Medicine, Columbia University Medical Center
- Education
- B.S. & B.A., 1994, Stanford University, Palo Alto, CA
- M.D., 1999, University of California Los Angeles School of Medicine
- Internship & Residency
- Internal Medicine, 2002, New York Presbyterian Hospital-Columbia University Medical Center, New York, NY
- Fellowship
- Hematology/Oncology, 2005, University of California, San Francisco
Ajai Chari, M.D.
NEW PATIENTS TEL (212) 305-5098
ADMINISTRATIVE OFFICE TEL (212) 305-0455
FAX (212) 305-0771
- OUTPATIENT OFFICE LOCATION
- Irving Pavilion 9
- 161 Fort Washington Ave at W 165th St.
- PHYSICIAN SUMMARY
- Ajai Chari, M.D. is an Assistant Professor of Medicine at the New York Presbyterian Hospital-Columbia University Medical Center. Dr. Chari cares for patients with cancers of the blood with an emphasis in multiple myeloma, Waldenstrom’s Macroglobulinemia, lymphoma, and chronic leukemia.
Dr. Chari received his undergraduate B.A. and B.S. degrees from Stanford University, where he was elected to Phi Beta Kappa. He matriculated at the University of California, Los Angeles (UCLA) School of Medicine and then received his Internal Medicine training at New York Presbyterian Hospital - Columbia University Medical Center. He completed his fellowship in Hematology and Medical Oncology at the University of California, San Francisco. He is currently involved in patient care, clinical research, and teaching on the hematology and bone marrow transplant services.
Dr. Chari is involved in clinical and translational research in plasma cell dyscrasias. He runs several clinical trials including phase I/II investigator initiated studies with novel agents/combinations of chemotherapeutic agents, high dose chemotherapy with autologous stem cell transplant, and national multi-center phase III cooperative group studies. Dr. Chari has served as a reviewer /moderator for the American Society of Hematology myeloma therapy abstracts and he is also a member of the Waldenstrom’s Research Consortium.
Particular areas of research interest include translational efforts in multiple myeloma with novel agents, markers of minimal residual disease after autologous stem cell transplant, and racial variation in clinical outcomes/cytogenetics of patients with plasma cell dyscrasias.